Clinical trials: Infection, Human Immunodeficiency Virus I
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
To determine the safety of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in human volunteers; to evaluate the immunogenicity of this preparation in human volunteers.
- Trial name
- NCT00000968
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, TB
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
This study is designed to evaluate the safety of MVA85A in asymptomatic volunteers in South Africa who are infected with M.tb, HIV or both.
- Trial name
- NCT00480558
- Testing
- MVA 85A
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- University of Oxford
HIV Infections, Pregnancy
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
To determine the bioavailability, pharmacokinetics, and short-term safety and tolerance of nevirapine in HIV-1 infected pregnant women and their newborns when nevirapine is given to the mother during active labor, and when their…
- Trial name
- NCT00000808
- Testing
- Nevirapine
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
To determine the safety of immunization with HIV-1 C4-V3 polyvalent peptide vaccine in HIV-infected persons. To determine the proportion of study participants immunized who develop new specificities or increased levels of…
- Trial name
- NCT00001060
- Testing
- HIV-1 C4-V3 Polyvalent Peptide Vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.
- Trial name
- NCT00219986
- Testing
- Potent HAART during acute or early HIV-1 infection
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV multiantigen vaccine MVA-mBN120B in HIV-infected subjects.
- Trial name
- NCT00623259
- Testing
- MVA-mBN120B
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bavarian Nordic
HIV Infections
Safety Study of UC-781 Vaginal Microbicide
This study will help determine whether UC-781 gel is safe when applied to the vagina twice daily for 14 days, and will assess whether women and men find the gel acceptable to use.
- Trial name
- NCT00446979
- Testing
- UC 781
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine
To evaluate the safety of LFn-p24 administered at three different doses with Alhydrogel given intramuscularly To evaluate immune responses to LFn-p24 with Alhydrogel at three different doses given intramuscularly
- Trial name
- NCT00412477
- Testing
- HIV LFn-p24
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART).
- Trial name
- NCT00006209
- Testing
- Tucaresol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Aaron Diamond AIDS Research Center
Acquired Immunodeficiency Syndrome, HIV Infections
A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection
This is a phase I/II study to determine the safety and tolerance of the protease inhibitor indinavir (MK-0639), alone and then in combination with HIV reverse transcriptase inhibitor therapy in children with HIV infection.
- Trial name
- NCT00001443
- Testing
- indinavir (MK-0639)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1, HIV Infections
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
This three stage study will evaluate the safety and tolerability of MRKAd5 HIV-1 Gag Vaccine. In Stage I subjects will be randomized to receive the vaccine at 1x10^9 viral particles/dose (vp/d) or placebo.
- Trial name
- NCT00849732
- Testing
- V520, Comparator: V520 (1x10^9 vp/d), Comparator: V520 (1x10^10 vp/d)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
The purpose of this study was to assess the safety and pharmacokinetics (PK) of three monoclonal antibodies, VRC01, VRC01LS, and VRC07-523LS, in HIV-exposed infants who are at increased risk of mother-to-child HIV transmission.
- Trial name
- NCT02256631
- Testing
- VRC01, VRC01LS, VRC07-523LS
- Where
- 14 sites in United States, Puerto Rico and 2 more
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples…
- Trial name
- NCT00107029
- Where
- 10 sites in United States
- Volunteers
- 113 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
The purpose of this study is to determine the effect of increased doses of lopinavir/ritonavir (LPV/r) and saquinavir (SQV) in HIV infected children who are failing their current antiretroviral regimen
- Trial name
- NCT00084058
- Testing
- Lopinavir/ritonavir, Saquinavir
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Probiotic Visbiome for Inflammation and Translocation in HIV Ι
Modern antiretroviral therapy (ART) has transformed the clinical care and lived experience of HIV infection. However, increased rates of adverse health conditions that are related to immune activation, such as cardiovascular…
- Trial name
- PROOV IT I (NCT02441244)
- Testing
- Visbiome
- Where
- 2 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Coronavirus
COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years…
- Trial name
- NCT04444674
- Testing
- ChAdOx1 nCoV-19, Normal saline 0.9%
- Where
- 7 sites in South Africa
- Volunteers
- 2,130 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Kaposi's Sarcoma
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients…
- Trial name
- NCT00686842
- Testing
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infections
Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to an HIV vaccine, administered using two different devices, followed by a vaccine boost, in healthy, HIV-uninfected adults.
- Trial name
- NCT01260727
- Testing
- PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine
- Where
- 4 sites in United States, Kenya and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The safety and immune responses will be studied in vaccine recipients.
- Trial name
- GCHT01 (NCT01428596)
- Testing
- HIVAX, saline solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GeneCure Biotechnologies
HIV Infections
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.
- Trial name
- NCT00428337
- Testing
- EP-1233, MVA-mBN32
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)